M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Patterns of delays in diagnosis amongst patients with smear-positive pulmonary tuberculosis at a teaching hospital in Turkey E. Okur, A. Yilmaz, A. Saygi,

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Herpes zoster in non-hospitalized children

E. Bronska, J. Kalmusova, O. Dzupova, V. Maresova, P. Kriz, J. Benes

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Candida glabrata fungaemia in intensive care units

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

R. Cantón Clinical Microbiology and Infection

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

E. Cambau, M. Drancourt Clinical Microbiology and Infection

Louis Pasteur, from crystals of life to vaccination

Chlamydia trachomatis infections in heterosexuals attending sexually transmitted disease clinics in Slovenia D. Kese, M. Maticic, M. Potocnik Clinical.

An eye-catching acanthocephalan

Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013 L.E.B. Nabarro, R.A. Lever, M. Armstrong,

Potential risk factors for infection with Candida spp

Prevalence of Toscana virus antibodies in residents of Croatia

Trends in length of stay, mortality and readmission among patients with community- acquired bacteraemia M. Søgaard, R.W. Thomsen, R.B. Bang, H.C. Schønheyder,

Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit.

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Myths, legends and realities of relapsing fever borreliosis

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Sofie Arens, Jan Verhaegen, Ludo Verbist

E. Bouza, P. Muñoz, R. Alonso Clinical Microbiology and Infection

Training for the infectious diseases speciality in Norway

G. Höffken Clinical Microbiology and Infection

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

B. Gordts Clinical Microbiology and Infection

Risk factors and mortality of healthcare-associated and community-acquired Staphylococcus aureus bacteraemia M. Bassetti, E.M. Trecarichi, A. Mesini,

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Metagenomics and probiotics

Recent developments in staphylococcal scalded skin syndrome

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

A. S. Hadziyannis, I. Stephanou, K. Dimarogona, A. Pantazatou, D

Systematic review of antibiotic consumption in acute care hospitals

Update on antifungal resistance in Aspergillus and Candida

Abstracts cont. Clinical Microbiology and Infection

Current experience in treating invasive zygomycosis with posaconazole

V. Vlahović-Palčevski, U. Dumpis, P. Mitt, J. Gulbinovič, J. Struwe, G

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS M. Rybicka,

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

An after-hours clinical liaison blood culture service—is it worth it?

Increasing numbers of hospitalizations and deaths with mention of Clostridium difficile infection, north-eastern Italy, 2008–2013 U. Fedeli, E. Schievano,

Statin use and clinical outcomes among pneumonia patients

Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria E. Presterl, F. Daxböck, W. Graninger,

W. Eugene Sanders, Christine C. Sanders

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij

The atypical pneumonias: clinical diagnosis and importance

Serum ferritin levels in West Nile encephalitis

Modelling during an emergency: the 2009 H1N1 influenza pandemic

R. Khatib, G. Simeunovic, M. Sharma, M. G. Fakih, L. B. Johnson, L

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Three years experience of real-time PCR for the diagnosis of Q fever

Bloodstream infections as a marker of community-acquired sepsis severity. Results from the Portuguese community-acquired sepsis study (SACiUCI study)

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Candidaemia in internal medicine departments: the burden of a rising problem M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi Clinical Microbiology and Infection Volume 19, Issue 6, Pages E281-E284 (June 2013) DOI: 10.1111/1469-0691.12155 Copyright © 2013 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Relationship between hospital mortality and the timing of antifungal treatment. The timing of antifungal therapy was determined to be from the time when the first blood sample for culture that was positive for fungi was drawn to the time when antifungal treatment was first administered to the patient. *p 0.03 between <48 h and >48 h or no therapy. Clinical Microbiology and Infection 2013 19, E281-E284DOI: (10.1111/1469-0691.12155) Copyright © 2013 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions